Obserwuj
Alberto Bardelli
Alberto Bardelli
University of Torino - Candiolo Cancer Institute IRCCS
Zweryfikowany adres z ircc.it
Tytuł
Cytowane przez
Cytowane przez
Rok
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ...
Science translational medicine 6 (224), 224ra24-224ra24, 2014
44382014
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Y Samuels, Z Wang, A Bardelli, N Silliman, J Ptak, S Szabo, H Yan, ...
Science 304 (5670), 554-554, 2004
41902004
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
32762016
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
25262010
Liquid biopsies: genotyping circulating tumor DNA
LA Diaz Jr, A Bardelli
Journal of clinical oncology 32 (6), 579, 2014
22472014
International network of cancer genome projects
Data coordination centre Kasprzyk (Leader) Arek 1 Stein (Leader) Lincoln D ...
Nature 464 (7291), 993-998, 2010
21672010
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
F Di Nicolantonio, M Martini, F Molinari, A Sartore Bianchi, S Arena, ...
Journal of clinical oncology 26 (35), 5705-5712, 2008
21172008
Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR
A Prahallad, C Sun, S Huang, F Di Nicolantonio, R Salazar, D Zecchin, ...
Nature 483 (7387), 100-103, 2012
21062012
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ...
Nature 486 (7404), 532-536, 2012
19592012
Liquid biopsy: monitoring cancer-genetics in the blood
E Crowley, F Di Nicolantonio, F Loupakis, A Bardelli
Nature reviews Clinical oncology 10 (8), 472-484, 2013
18272013
Integrating liquid biopsies into the management of cancer
G Siravegna, S Marsoni, S Siena, A Bardelli
Nature reviews Clinical oncology 14 (9), 531-548, 2017
16232017
RAF/RAS oncogenes and mismatch-repair status
H Rajagopalan, A Bardelli, C Lengauer, KW Kinzler, B Vogelstein, ...
Nature 418 (6901), 934-934, 2002
15992002
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family
C Ponzetto, A Bardelli, Z Zhen, F Maina, P dalla Zonca, S Giordano, ...
Cell 77 (2), 261-271, 1994
12021994
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ...
The lancet oncology 6 (5), 279-286, 2005
11592005
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies
S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ...
Cancer research 67 (6), 2643-2648, 2007
10612007
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
10522015
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ...
Cancer discovery 1 (6), 508-523, 2011
970*2011
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ...
Cancer research 69 (5), 1851-1857, 2009
9042009
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
8942016
A phosphatase associated with metastasis of colorectal cancer
S Saha, A Bardelli, P Buckhaults, VE Velculescu, C Rago, BS Croix, ...
Science 294 (5545), 1343-1346, 2001
8762001
Nie można teraz wykonać tej operacji. Spróbuj ponownie później.
Prace 1–20